A citation-based method for searching scientific literature


List of co-cited articles
811 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor.
R G Chirivi, A Garofalo, M J Crimmin, L J Bawden, A Stoppacciaro, P D Brown, R Giavazzi. Int J Cancer 1994
181
28




Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340.
A Price, Q Shi, D Morris, M E Wilcox, P M Brasher, N B Rewcastle, D Shalinsky, H Zou, K Appelt, R N Johnston,[...]. Clin Cancer Res 1999
120
14

Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials.
D R Shalinsky, J Brekken, H Zou, C D McDermott, P Forsyth, D Edwards, S Margosiak, S Bender, G Truitt, A Wood,[...]. Ann N Y Acad Sci 1999
200
14


Matrix metalloproteinase inhibitors.
S M Wojtowicz-Praga, R B Dickson, M J Hawkins. Invest New Drugs 1997
350
13

Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases.
G Taraboletti, A Garofalo, D Belotti, T Drudis, P Borsotti, E Scanziani, P D Brown, R Giavazzi. J Natl Cancer Inst 1995
201
13


Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts.
R Giavazzi, A Garofalo, C Ferri, V Lucchini, E A Bone, S Chiari, P D Brown, M I Nicoletti, G Taraboletti. Clin Cancer Res 1998
70
17



Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer.
G I Murray, M E Duncan, P O'Neil, W T Melvin, J E Fothergill. Nat Med 1996
408
11

Reduced angiogenesis and tumor progression in gelatinase A-deficient mice.
T Itoh, M Tanioka, H Yoshida, T Yoshioka, H Nishimoto, S Itohara. Cancer Res 1998
740
11

Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer.
S Wojtowicz-Praga, J Torri, M Johnson, V Steen, J Marshall, E Ness, R Dickson, M Sale, H S Rasmussen, T A Chiodo,[...]. J Clin Oncol 1998
200
11



Changing views of the role of matrix metalloproteinases in metastasis.
A F Chambers, L M Matrisian. J Natl Cancer Inst 1997
10


Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions.
V M Macaulay, K J O'Byrne, M P Saunders, J P Braybrooke, L Long, F Gleeson, C S Mason, A L Harris, P Brown, D C Talbot. Clin Cancer Res 1999
121
10

Development of matrix metalloproteinase inhibitors in cancer therapy.
M Hidalgo, S G Eckhardt. J Natl Cancer Inst 2001
587
10

Conversion of highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor.
Z An, X Wang, N Willmott, S K Chander, S Tickle, A J Docherty, A Mountain, A T Millican, R Morphy, J R Porter,[...]. Clin Exp Metastasis 1997
53
18



Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin.
C L Wilson, K J Heppner, P A Labosky, B L Hogan, L M Matrisian. Proc Natl Acad Sci U S A 1997
509
9

Matrix metalloproteinase inhibitors and cancer: trials and tribulations.
Lisa M Coussens, Barbara Fingleton, Lynn M Matrisian. Science 2002
9


A matrix metalloproteinase expressed on the surface of invasive tumour cells.
H Sato, T Takino, Y Okada, J Cao, A Shinagawa, E Yamamoto, M Seiki. Nature 1994
8

Matrix metalloproteinases: biologic activity and clinical implications.
A R Nelson, B Fingleton, M L Rothenberg, L M Matrisian. J Clin Oncol 2000
8

Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies.
E K Rowinsky, R Humphrey, L A Hammond, C Aylesworth, L Smetzer, M Hidalgo, M Morrow, L Smith, A Garner, J M Sorensen,[...]. J Clin Oncol 2000
74
10


Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial.
S R Bramhall, A Rosemurgy, P D Brown, C Bowry, J A Buckels. J Clin Oncol 2001
334
8

Expression and localization of matrix-degrading metalloproteinases during colorectal tumorigenesis.
K J Newell, J P Witty, W H Rodgers, L M Matrisian. Mol Carcinog 1994
228
7




Tissue inhibitors of metalloproteinases: structure, regulation and biological functions.
D E Gomez, D F Alonso, H Yoshiji, U P Thorgeirsson. Eur J Cell Biol 1997
7

Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer.
S Wojtowicz-Praga, J Low, J Marshall, E Ness, R Dickson, J Barter, M Sale, P McCann, J Moore, A Cole,[...]. Invest New Drugs 1996
90
7


How matrix metalloproteinases regulate cell behavior.
M D Sternlicht, Z Werb. Annu Rev Cell Dev Biol 2001
7

Matrilysin-specific antisense oligonucleotide inhibits liver metastasis of human colon cancer cells in a nude mouse model.
S Hasegawa, N Koshikawa, N Momiyama, K Moriyama, Y Ichikawa, T Ishikawa, M Mitsuhashi, H Shimada, K Miyazaki. Int J Cancer 1998
85
7




Effects of angiogenesis inhibitors on multistage carcinogenesis in mice.
G Bergers, K Javaherian, K M Lo, J Folkman, D Hanahan. Science 1999
810
6

Tumor targeting with a selective gelatinase inhibitor.
E Koivunen, W Arap, H Valtanen, A Rainisalo, O P Medina, P Heikkilä, C Kantor, C G Gahmberg, T Salo, Y T Konttinen,[...]. Nat Biotechnol 1999
455
6


Preventive effect of matrix metalloproteinase inhibitor, R-94138, in combination with mitomycin C or cisplatin on peritoneal dissemination of human gastric cancer cell line TMK-1 in nude mice.
N Igarashi, T Kubota, Y Otani, S W Matsuzaki, M Watanabe, T Teramoto, K Kumai, K Tamaki, K Tanzawa, T Kobayashi,[...]. Jpn J Cancer Res 1999
19
31


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.